Evaluation of a vaporizing device (Volcano®) for the pulmonary administration of tetrahydrocannabinol

Journal of Pharmaceutical Sciences

Volumn 95, Issue 6, 2006, Pages 1308-1317

  Hazekamp, Arno ^a   Ruhaak, Renee ^a   Zuurman, Lineke ^b   Van Gerven, Joop ^b   Verpoorte, Rob ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

Aerosol; Cannabis; Controlled delivery; Delta 9 tetrahydrocannabinol; Formulation vehicle; Pulmonary drug delivery; Vaporizer

Indexed keywords

CANNABINOID; DELTA8 TETRAHYDROCANNABINOL; TETRAHYDROCANNABINOL;

AEROSOL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; NONHUMAN; REPRODUCIBILITY; SMOKING; TEMPERATURE SENSITIVITY; VAPORIZATION; VAPORIZER;

EID: 33745019364     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20574     Document Type: Article

References (29)

1. Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC. 2003. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 30:201-205.
2. Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R. 2004. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDS 18:215-228.
3. Grinspoon L. 1997. Marijuana, the forbidden medicine. Revised edition. New Haven, CT: Yale University Press.
4. Hiller FC, Wilson FJJ, Mazumder MK, Wilson JD, Bone RC. 1984. Concentration and particle size distribution in smoke from marijuana cigarettes with different A9-tetrahydrocannabinol content. Fundam Appl Toxicol 4:451-454.
5. Matthias P, Tashkin DP, Marques-Magallanes JA, Wilkins JN, Simmons MS. 1997. Effects of varying marijuana potency on deposition of tar and delta9-THC in the lung during smoking. Pharmacol Biochem Behav 58:1145-1150.
6. Institute of Medicine. 1999. Marijuana and medicine: Assessing the scientific base. Washington DC, MD: National Academy Press.
7. Gieringer D. 1996. Marijuana research: Waterpipe study. MAPS (Multidisciplinary Association for Psychedelic Studies) Bull 6:59-66.
8. McPartland JM, Pruitt PL. 1997. Medical marijuana and its use by the immunocompromised. Altern Ther Health Med 3:39-45.
9. Chemic Laboratories. 2000. Proof of concept: Release of chemical constituents in cannabis sativa at 170-185°C versus combustion. Unpublished report to California NORML and MAPS, Nov 17th, 2000.
10. Gieringer D. 2001. Cannabis vaporization: A promising strategy for smoke harm reduction. J Cannabis Ther 1:153-170.
11. Gieringer D, StLaurent J, Goodrich S. 2004. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther 4:7-27.
12. http://www.storz-bickel.de, website visited 10 January 2005.
13. Hazekamp A, Simons R, Peltenburg-Looman A, Sengers M, van Zweden R, Verpoorte R. 2004a. Preparative isolation of cannabinoids from Cannabis sativa by centrifugal partition chromatography. J Liq Chrom Rel Technol 27:2421-2439.
14. 1H-NMR. Chem Pharm Bull 52:718-721.
15. Hazekamp A, Giroud C, Peltenburg A, Verpoorte R. 2005. Spectroscopic and chromatographic data of cannabinoids from Cannabis sativa. J Liq Chrom Rel Technol 28:2361-2382.
16. Zuurman L, Roy C, Hazekamp A, Schoemaker R, den Hartigh J, Bender JCME, Pinquier JL, Cohen AF, van Gerven JMA. 2005. Effect of THC administration in humans: Methodology study for further pharmacodynamic studies with cannabinoid agonist or antagonist. Br J Clin Pharmacol 59:625.
17. Leweke FM. 2002. Acute effects of cannabis and the cannabinoids. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. New York, NY: Haworth Press, pp 249-256.
18. Abood ME, Martin BR. 1992. Neurobiology of marijuana abuse. Trends Pharmacol Sci 13:201-206.
19. Fehr KO, Kalant H. 1972. Analysis of cannabis smoke obtained under different combustion conditions. Can J Physiol Pharmacol 50:761-767.
20. Manno JE, Kiplinger GF, Haine SE, Bennett IF, Forney RB. 1970. Comparative effects of smoking marihuana or placebo on human motor performance. Clin Pharmacol Ther 11:808-815.
21. Davis KH. 1984. Some smoking characteristics of marijuana cigarettes. In: Agurell S, Dewey WL, Willette RE, editors. The cannabinoids: Chemical, pharmacologic and therapeutic aspects. New York, NY: Academic Press.
22. Edery H, Grunfeld Y, Porath G, Ben-Zvi Z, Shani A, Mechoulam R. 1972. Structure-activity relationships in the tetrahydrocannabinol series. Modifications on the aromatic ring and it the side-chain. Arzneimittelforschung 22:1995-2003.
23. 9-THC aerosol generated by a metered dose inhaler. Drug Alcohol Depend 67:259-267.
24. Naef M, Russmann S, Petersen-Felix S, Brenneisen R. 2004. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharm Sci 93:1176-1184.
25. Lichtman AH, Peart J, Poklis JL, Bridgen DT, Razdan RK, Wilson DM, Poklis A, Meng Y, Byron PR, Martin BR. 2000. Pharmacological evaluation of aerosolized cannabinoids in mice. Eur J Pharmacol 399:141-149.
26. Hartley JP, Nogrady SG, Seaton A. 1978. Bronchodilator effect of deltal-tetrahydrocannabinol. Br J Clin Pharmacol 5:523-525.
27. Lyons HA, Ayres SM, Dworetzky M, Failliers CS, Harris MC, Dollery CT, Gandevia B. 1973. Symposium on isoproterenol therapy in asthma. Ann Allergy 31:1-44.
28. Williamson EM, Evans FJ. 2000. Cannabinoids in clinical practice. Drugs 60:1303-1314.
29. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C. 2004. Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1' studies. Anaesthesia 59:440-452.